Prostate cancer detection is also relevant in low prostate specific antigen ranges

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• Prostate cancer (PCa) screening programs aim to detect cancer early.
• Low prostate specific antigen (PSA) levels can sometimes be associated with PCa.
• Understanding detection rates and cancer characteristics at low PSA is crucial for screening protocols.

Purpose of the Study:

• To determine the detection rates of prostate cancer (PCa) in men with low prostate specific antigen (PSA) levels.
• To analyze the clinical features of PCa detected at low PSA ranges.
• To assess the significance of cancers found with PSA between 1.0-2.99 ng/ml and 3.0-3.99 ng/ml.

Main Methods:

• Analysis of data from 1097 men in a PCa screening program.
• Biopsy recommendations based on PSA levels (≥3 ng/ml) and free to total PSA ratio (<20% for PSA 1.0-2.99 ng/ml).
• Calculation of cancer detection rates and evaluation of clinical features for detected cancers.

Main Results:

• 15 cancers detected in the PSA range 1.0-2.99 ng/ml (9.4% detection rate) and 12 cancers in the 3.0-3.99 ng/ml range (21.4% detection rate).
• All detected cancers were clinically localized.
• A significant proportion of cancers in the low PSA range (1.0-2.99 ng/ml) did not meet criteria for insignificant cancer, with some showing aggressive features.

Conclusions:

• Cancer detection rates are lower in low PSA ranges but remain clinically relevant.
• The detection of potentially aggressive prostate cancers in men with low PSA levels is a significant concern.
• Current screening strategies should consider the implications of findings in lower PSA ranges.